{"id":"NCT02460978","sponsor":"AstraZeneca","briefTitle":"Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-08","primaryCompletion":"2017-09-02","completion":"2018-04-18","firstPosted":"2015-06-03","resultsPosted":"2018-11-06","lastUpdate":"2019-03-05"},"enrollment":815,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":[]},{"type":"OTHER","name":"Placebo for dapagliflozin","otherNames":[]}],"arms":[{"label":"Dapagliflozin 5 mg","type":"EXPERIMENTAL"},{"label":"Dapagliflozin 10 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline in HbA1c at Week 24","timeFrame":"Baseline and 24 weeks","effectByArm":[{"arm":"DAPA 5 MG + INS","deltaMin":-0.34,"sd":null},{"arm":"DAPA 10 MG + INS","deltaMin":-0.39,"sd":null},{"arm":"PLA + INS","deltaMin":0.03,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":8},"locations":{"siteCount":136,"countries":["United States","Argentina","Belgium","Canada","Chile","Germany","Japan","Netherlands","Poland","Russia","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["39918875","38770818","35403243","32946821","32691513","30756462","30026335"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4122&filename=MB102230_CSP.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4122&filename=MB102230_SAP.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":271},"commonTop":["Viral upper respiratory tract infection","Pollakiuria","Upper respiratory tract infection","Headache","Thirst"]}}